Rethinking Osteoarthritis: Targeting Inflammation in Dogs With Dr. Tarantino episode artwork

EPISODE · Jun 18, 2026 · 25 MIN

Rethinking Osteoarthritis: Targeting Inflammation in Dogs With Dr. Tarantino

from Clinician's Brief: The Podcast · host Brief Media

As our understanding of canine osteoarthritis deepens and treatment options continue to expand, there's never been a better opportunity to refine how we approach this disease in practice. In this episode of the Partner Podcast, Dr. Beth invites Dr. Monica Tarantino to explore what's actually happening in the arthritic joint, why inflammation deserves its own place in the treatment conversation, and how she navigates anti-inflammatory options in her senior patients. Sponsored by Elanco Indication Galliprant controls pain and inflammation associated with osteoarthritis in dogs.Important Safety Information For use in dogs only. Keep this and all medications out of reach of children and pets to prevent accidental ingestion or overdose. Galliprant is a non-COX inhibiting NSAID. As a class, NSAIDs may be associated with gastrointestinal, kidney and liver side effects. Evaluation for pre-existing conditions and regular monitoring are recommended. Do not use in dogs that have a hypersensitivity to grapiprant. Concomitant use of Galliprant with other NSAIDs or corticosteroids should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. Owners should be advised to observe for signs of potential drug toxicity. Adverse reactions may include vomiting, diarrhea, decreased appetite, watery or bloody stools, and decreases in serum albumin and total protein. Click here for full prescribing information.  Contact us: [email protected] Where to find us: Website: CliniciansBrief.com/Podcasts YouTube: Youtube.com/@clinicians_brief Facebook: Facebook.com/CliniciansBrief LinkedIn: LinkedIn.com/showcase/CliniciansBrief/ X: @cliniciansbrief Instagram: @clinicians.brief The Team: Beth Molleson, DVM - Host Sarah Pate - Producer & Project Manager, Brief Studio Taylor Argo- Podcast Production & Sound Editing  

As our understanding of canine osteoarthritis deepens and treatment options continue to expand, there's never been a better opportunity to refine how we approach this disease in practice. In this episode of the Partner Podcast, Dr. Beth invites Dr. Monica Tarantino to explore what's actually happening in the arthritic joint, why inflammation deserves its own place in the treatment conversation, and how she navigates anti-inflammatory options in her senior patients. Sponsored by Elanco Indication Galliprant controls pain and inflammation associated with osteoarthritis in dogs. Important Safety Information For use in dogs only. Keep this and all medications out of reach of children and pets to prevent accidental ingestion or overdose. Galliprant is a non-COX inhibiting NSAID. As a class, NSAIDs may be associated with gastrointestinal, kidney and liver side effects. Evaluation for pre-existing conditions and regular monitoring are recommended. Do not use in dogs that have a hypersensitivity to grapiprant. Concomitant use of Galliprant with other NSAIDs or corticosteroids should be avoided. Concurrent use with other anti-inflammatory drugs or protein-bound drugs has not been studied. The safe use of Galliprant has not been evaluated in dogs younger than 9 months of age and less than 8 lbs (3.6 kg), dogs used for breeding, pregnant or lactating dogs, or dogs with cardiac disease. Owners should be advised to observe for signs of potential drug toxicity. Adverse reactions may include vomiting, diarrhea, decreased appetite, watery or bloody stools, and decreases in serum albumin and total protein. Visit http://elancolabels.com/us/galliprant for full prescribing information. Contact us: [email protected] Where to find us: Website: CliniciansBrief.com/Podcasts YouTube: Youtube.com/@clinicians_brief Facebook: Facebook.com/CliniciansBrief LinkedIn: LinkedIn.com/showcase/CliniciansBrief/ X: @cliniciansbrief Instagram: @clinicians.brief The Team: Beth Molleson, DVM - Host Sarah Pate - Producer & Project Manager, Brief Studio Taylor Argo- Podcast Production & Sound Editing

NOW PLAYING

Rethinking Osteoarthritis: Targeting Inflammation in Dogs With Dr. Tarantino

0:00 25:41

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Clinician's Brief: The Podcast?

This episode is 25 minutes long.

When was this Clinician's Brief: The Podcast episode published?

This episode was published on June 18, 2026.

What is this episode about?

As our understanding of canine osteoarthritis deepens and treatment options continue to expand, there's never been a better opportunity to refine how we approach this disease in practice. In this episode of the Partner Podcast, Dr. Beth invites Dr....

Can I download this Clinician's Brief: The Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!